Sun Pharma: Ilumya illuminates
The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms
August 02, 2021 / 10:13 AM IST
PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook
Sun Pharma, India’s largest pharma company, (CMP: Rs 774, Market Cap: Rs 1,85,697 crore) appears to be doing well on the specialty products front, particularly as the re-opening of the US economy facilitates new products & clinical trials.
Sales of specialty products during the reporting quarter, clocked $148 million against $139 million in Q4 FY21 and $78 million in Q1 FY21. Growth was supported by traction for the Ilumya and the Cequa, used to treat plaque psoriasis and dry-eye disease...